Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Complex generics,...

    Complex generics, proprietary products to drive growth: Dr Reddy's Labs

    Written by savita thakur thakur Published On 2016-07-18T14:15:30+05:30  |  Updated On 18 July 2016 2:15 PM IST

    New Delhi : Dr Reddy's Laboratories (DRL) expects complex generics, proprietary products, including creation of branded generics platform in the US, to be the main drivers of its growth going forward.


    "Our growth, going forward, will be driven by the attractive pipeline of complex generics as well as our new proprietary products," Dr Reddy's Laboratories Chairman K Satish Reddy said in a message in the company's latest annual report.


    The company will leverage these across the markets we operate in, together with increasing our OTC portfolio, he added.


    Highlighting the roadmap the company is taking for expansion, Reddy said, "we are creating a branded generics platform in North America and expanding our biologics play in Russia, CIS and other emerging markets".


    The outlook for the API business is also positive, he added.


    A branded generic is a drug that is bioequivalent to the original product, but is now marketed under another company's brand name.


    During the fiscal year 2015-16, the company's revenues from North America for generics grew 19 per cent to Rs 7,540 crore during 2015-16.


    "The sustained performance of our injectables franchise and market share gains in key molecules were the main reason," Reddy said.


    Dr Reddy's Laboratories had posted a consolidated net income from sales and services of Rs 15,470.8 crore for 2015-16 fiscal. It was Rs 14,818.9 crore in the previous fiscal.


    About the other global markets, Reddy said "it is difficult to assess the probable situation in Venezuela and Russia in the near future."


    In case of Venezuela, the company has decided to supply medicines only against letters of credit or pre-payment, he added.


    "We are cautiously optimistic about Russia, given that there is a gradual recovery in the crude prices, and its direct impact on the rouble," he added.

    APIcomplex genericsDr Reddy'sDRLK Satish ReddymoleculesOTCproprietary products
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok